Myriad Genetics(NASDAQ) MYGN

Myriad Genetics makes DNA tests to find health risks. These tools help doctors choose the right treatments for patients. Parents use them to check for genetic disorders during pregnancy.

The Genetic Testing Menu

• Cancer Care Continuum: DNA sequencing and tumor tests that assess hereditary cancer risk and guide therapy selection; accounted for 60% of revenue in the first quarter of 2026.
• Prenatal Health: Screening tools that check maternal blood for fetal chromosomal disorders or identify recessive conditions in future parents; made up 21% of revenue in the first quarter of 2026.
• Mental Health: Genetic tests used to help clinicians select the most effective psychotropic medications for depression and anxiety; represented 19% of revenue in the first quarter of 2026.

Building the Pipeline

• Launched the Precise MRD test in March 2026 to detect minimal residual disease, which are small amounts of cancer cells left in the body after treatment.
• Received FDA approval in March 2026 for MyChoice CDx, a companion diagnostic used to identify patients eligible for specific ovarian cancer drugs.
• Formed a strategic collaboration with Illumina and Intermountain Precision Genomics to provide combined germline and tumor testing services.
• Expanded the Salt Lake City headquarters in early 2026 to provide additional laboratory space for future operating needs.

The Clinical Advantage

Myriad relies on an extensive commercial network in community medicine to distribute its diagnostic tools. The company focuses on integrating genetic insights directly into clinical workflows to speed up treatment decisions and improve patient outcomes.

The Recent Scorecard

• Revenue reached $200.4 million in the first quarter of 2026, representing a 2.3% increase from the prior year.
• Gross profit rose to $137.6 million in the first quarter of 2026, up 2.5% year-over-year.
• Operating loss widened to $30.7 million in the first quarter of 2026, compared to a $29 million loss in the same period of 2025.
• Net loss deepened to $34.1 million in the first quarter of 2026, worsening from a $100,000 loss in the first quarter of 2025.
• Cash and cash equivalents stood at $124.4 million as of March 31, 2026, down from $149.6 million at the end of 2025.

Bottom Line

Myriad has evolved into a diversified diagnostic company covering cancer, prenatal, and mental health markets. Its long-term trajectory depends on successfully scaling new product launches like Precise MRD while managing significant quarterly operating losses.